These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 3428309

  • 1. Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
    Chouza C, Romero S, de Medina O, Aljanati R, Scarmelli A, Caamano JL, Gonzales Panizza V.
    Eur Neurol; 1987; 27 Suppl 1():59-67. PubMed ID: 3428309
    [Abstract] [Full Text] [Related]

  • 2. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
    Jansen EN, Meerwaldt JD, Heersema T, van Manen J, Speelman JD.
    Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
    Fischer PA, Baas H.
    Eur Neurol; 1987; 27 Suppl 1():81-7. PubMed ID: 3322840
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
    Rinne UK.
    Eur Neurol; 1987; 27 Suppl 1():120-5. PubMed ID: 3428305
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Open clinical study of Madopar HBS.
    Ludin HP.
    Eur Neurol; 1987; 27 Suppl 1():73-5. PubMed ID: 3322838
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
    Rondot P, Ziegler M, Aymard N, Holzer J.
    Eur Neurol; 1987; 27 Suppl 1():114-9. PubMed ID: 3322835
    [Abstract] [Full Text] [Related]

  • 13. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
    Lees AJ.
    Eur Neurol; 1987; 27 Suppl 1():126-34. PubMed ID: 3428306
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE.
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
    Chouza C, Aljanati R, Caamaño JL, De Medina O, Scaramelli A, Buzó R, Plachín V, Fernandez A, Romero S.
    Adv Neurol; 1990; 53():519-26. PubMed ID: 2122654
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.